Stifel Downgrades Treace Medical Concepts to Hold, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise downgraded Treace Medical Concepts (TMCI) from Buy to Hold and reduced the price target from $15 to $6.

May 08, 2024 | 10:26 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Stifel downgraded Treace Medical Concepts to Hold and lowered the price target to $6.
Analyst downgrades typically lead to a negative short-term reaction in the stock price, especially with a significant reduction in the price target. This downgrade from Buy to Hold, coupled with a substantial decrease in the price target from $15 to $6, suggests a bearish outlook on TMCI's future performance, likely impacting investor sentiment and potentially leading to a decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100